FDA Clears Dexcom Stelo as First OTC Continuous Glucose Monitor for Children
Key Dates
What Happened
On June 12, 2026, the FDA cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children as young as two who do not use insulin, the first OTC continuous glucose monitor indicated for a pediatric population. The clearance relied on real-world evidence, combining prior pediatric and adult clinical study data with real-world integrated-CGM use data rather than a dedicated pediatric trial. The wearable sensor pairs with an app, including a parent's or caregiver's smartphone, and displays glucose readings every 15 minutes. Stelo was originally cleared in 2024 for adults 18 and older.
Who It Affects
Children 2 and older who do not use insulin, including those managing diabetes with oral medications and those tracking how diet and exercise affect glucose. The system is not indicated for individuals with problematic hypoglycemia because it does not issue low-glucose alerts. The over-the-counter, no-prescription pathway puts a pediatric CGM directly in the consumer and retail channel rather than only through clinical prescribing.
Business Implications
Opening the OTC CGM category to children moves continuous metabolic monitoring into a direct-to-consumer pediatric channel for the first time, with implications for pediatric metabolic-health, digital-coaching, and remote-monitoring companies that can build on consumer biosensor data. The real-world-evidence regulatory pathway, with no dedicated pediatric trial, is itself a notable precedent for pediatric device expansion. Pairs with the same-day Tzield pediatric Stage 3 T1D approval as a "diabetes incumbents entering pediatrics" signal worth watching.
Sources
- FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
- In a first, Dexcom's OTC glucose sensor is cleared for kids — MedTech Dive
Also featured in: The Week in Maternal-Pediatric Health Tech (June 23) — Tuesday Roundup